Advances in Dermatology: 2024 in Review by Cather McKay, MD
Advances in Dermatology: 2024 in Review By Cather McKay, MD The past year has been another exciting one in the field of dermatology! New medications and expanded indications give us more options than ever to care for our patients. Atopic dermatitis and prurigo nodularis More topical options for atopic dermatitis (AD) became available this year with the approval of roflumilast 0.15% cream (Zoryve) in patients aged 6 years and up and tapinarof 1% cream (Vtama) in patients aged 2 years and up. 1,2 Approval of the pan-JAK inhibitor delgocitinib cream for adults with chronic hand eczema is expected based on phase 3 trials. 3 Ruxolitinib cream (Opzelura) is currently approved for ages 12 and up, but has shown safety and efficacy in patients as young as 2 years. 4 IL-13 inhibitor lebrikizumab (Ebglyss) was approved in September for moderate to severe AD in patients 12 years and up who weigh at least 40 kg. 5 Another IL-13 inhibitor, cendakimab, is in develo...